Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Blood. 2015 May 21;125(21):3357-9. doi: 10.1182/blood-2015-03-633156.

Authors

Chan Yoon Cheah¹, Loretta J Nastoupil¹, Sattva S Neelapu¹, Sheryl G Forbes¹, Yasuhiro Oki¹, Nathan H Fowler¹

Affiliation

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Female
Humans
Lenalidomide
Lymphoma / drug therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Purines / administration & dosage
Purines / adverse effects
Quinazolinones / administration & dosage
Quinazolinones / adverse effects
Rituximab
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives

Substances

Antibodies, Monoclonal, Murine-Derived
Purines
Quinazolinones
Rituximab
Thalidomide
Lenalidomide
idelalisib